Cargando…

A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study

OBJECTIVE: This paper explores the use of pharmacoeconomic methods of valuation to health impacts resulting from exposure to poor air quality. In using such methods, interventions that reduce exposure to poor air quality can be directly compared, in terms of value for money (or cost-effectiveness),...

Descripción completa

Detalles Bibliográficos
Autores principales: Lomas, James, Schmitt, Laetitia, Jones, Sally, McGeorge, Maureen, Bates, Elizabeth, Holland, Mike, Cooper, Duncan, Crowther, Richard, Ashmore, Mike, Rojas-Rueda, David, Weatherly, Helen, Richardson, Gerry, Bojke, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916570/
https://www.ncbi.nlm.nih.gov/pubmed/27329439
http://dx.doi.org/10.1136/bmjopen-2015-010686
_version_ 1782438850969206784
author Lomas, James
Schmitt, Laetitia
Jones, Sally
McGeorge, Maureen
Bates, Elizabeth
Holland, Mike
Cooper, Duncan
Crowther, Richard
Ashmore, Mike
Rojas-Rueda, David
Weatherly, Helen
Richardson, Gerry
Bojke, Laura
author_facet Lomas, James
Schmitt, Laetitia
Jones, Sally
McGeorge, Maureen
Bates, Elizabeth
Holland, Mike
Cooper, Duncan
Crowther, Richard
Ashmore, Mike
Rojas-Rueda, David
Weatherly, Helen
Richardson, Gerry
Bojke, Laura
author_sort Lomas, James
collection PubMed
description OBJECTIVE: This paper explores the use of pharmacoeconomic methods of valuation to health impacts resulting from exposure to poor air quality. In using such methods, interventions that reduce exposure to poor air quality can be directly compared, in terms of value for money (or cost-effectiveness), with competing demands for finite resources, including other public health interventions. DESIGN: Using results estimated as part of a health impact assessment regarding a West Yorkshire Low Emission Zone strategy, this paper quantifies cost-saving and health-improving implications of transport policy through its impact on air quality. DATA SOURCE: Estimates of health-related quality of life and the National Health Service (NHS)/Personal Social Services (PSS) costs for identified health events were based on data from Leeds and Bradford using peer-reviewed publications or Office for National Statistics releases. POPULATION: Inhabitants of the area within the outer ring roads of Leeds and Bradford. MAIN OUTCOMES MEASURES: NHS and PSS costs and quality-adjusted life years (QALYs). RESULTS: Averting an all-cause mortality death generates 8.4 QALYs. Each coronary event avoided saves £28 000 in NHS/PSS costs and generates 1.1 QALYs. For every fewer case of childhood asthma, there will be NHS/PSS cost saving of £3000 and a health benefit of 0.9 QALYs. A single term, low birthweight birth avoided saves £2000 in NHS/PSS costs. Preventing a preterm birth saves £24 000 in NHS/PSS costs and generates 1.3 QALYs. A scenario modelled in the West Yorkshire Low Emission Zone Feasibility Study, where pre-EURO 4 buses and HGVs are upgraded to EURO 6 by 2016 generates an annual benefit of £2.08 million and a one-off benefit of £3.3 million compared with a net present value cost of implementation of £6.3 million. CONCLUSIONS: Interventions to improve air quality and health should be evaluated and where improvement of population health is the primary objective, cost-effectiveness analysis using a NHS/PSS costs and QALYs framework is an appropriate methodology.
format Online
Article
Text
id pubmed-4916570
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-49165702016-06-24 A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study Lomas, James Schmitt, Laetitia Jones, Sally McGeorge, Maureen Bates, Elizabeth Holland, Mike Cooper, Duncan Crowther, Richard Ashmore, Mike Rojas-Rueda, David Weatherly, Helen Richardson, Gerry Bojke, Laura BMJ Open Public Health OBJECTIVE: This paper explores the use of pharmacoeconomic methods of valuation to health impacts resulting from exposure to poor air quality. In using such methods, interventions that reduce exposure to poor air quality can be directly compared, in terms of value for money (or cost-effectiveness), with competing demands for finite resources, including other public health interventions. DESIGN: Using results estimated as part of a health impact assessment regarding a West Yorkshire Low Emission Zone strategy, this paper quantifies cost-saving and health-improving implications of transport policy through its impact on air quality. DATA SOURCE: Estimates of health-related quality of life and the National Health Service (NHS)/Personal Social Services (PSS) costs for identified health events were based on data from Leeds and Bradford using peer-reviewed publications or Office for National Statistics releases. POPULATION: Inhabitants of the area within the outer ring roads of Leeds and Bradford. MAIN OUTCOMES MEASURES: NHS and PSS costs and quality-adjusted life years (QALYs). RESULTS: Averting an all-cause mortality death generates 8.4 QALYs. Each coronary event avoided saves £28 000 in NHS/PSS costs and generates 1.1 QALYs. For every fewer case of childhood asthma, there will be NHS/PSS cost saving of £3000 and a health benefit of 0.9 QALYs. A single term, low birthweight birth avoided saves £2000 in NHS/PSS costs. Preventing a preterm birth saves £24 000 in NHS/PSS costs and generates 1.3 QALYs. A scenario modelled in the West Yorkshire Low Emission Zone Feasibility Study, where pre-EURO 4 buses and HGVs are upgraded to EURO 6 by 2016 generates an annual benefit of £2.08 million and a one-off benefit of £3.3 million compared with a net present value cost of implementation of £6.3 million. CONCLUSIONS: Interventions to improve air quality and health should be evaluated and where improvement of population health is the primary objective, cost-effectiveness analysis using a NHS/PSS costs and QALYs framework is an appropriate methodology. BMJ Publishing Group 2016-06-21 /pmc/articles/PMC4916570/ /pubmed/27329439 http://dx.doi.org/10.1136/bmjopen-2015-010686 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
spellingShingle Public Health
Lomas, James
Schmitt, Laetitia
Jones, Sally
McGeorge, Maureen
Bates, Elizabeth
Holland, Mike
Cooper, Duncan
Crowther, Richard
Ashmore, Mike
Rojas-Rueda, David
Weatherly, Helen
Richardson, Gerry
Bojke, Laura
A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study
title A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study
title_full A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study
title_fullStr A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study
title_full_unstemmed A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study
title_short A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study
title_sort pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916570/
https://www.ncbi.nlm.nih.gov/pubmed/27329439
http://dx.doi.org/10.1136/bmjopen-2015-010686
work_keys_str_mv AT lomasjames apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT schmittlaetitia apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT jonessally apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT mcgeorgemaureen apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT bateselizabeth apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT hollandmike apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT cooperduncan apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT crowtherrichard apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT ashmoremike apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT rojasruedadavid apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT weatherlyhelen apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT richardsongerry apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT bojkelaura apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT lomasjames pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT schmittlaetitia pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT jonessally pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT mcgeorgemaureen pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT bateselizabeth pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT hollandmike pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT cooperduncan pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT crowtherrichard pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT ashmoremike pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT rojasruedadavid pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT weatherlyhelen pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT richardsongerry pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy
AT bojkelaura pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy